• SNAI1, EMT, and Stemness in Thymic Tumors

  2026-10-07

  A 2024 study identifies SNAI1 as a transcriptional hub associated with invasiveness, epithelial–mesenchymal transition, and cancer stem cell-like properties in thymic epithelial tumors. Multi-omics and functional evidence connects SNAI1 to PIK3R2, phosphorylated EphA2, and downstream GSK3β/β-catenin signaling, while also implicating macrophage-state changes in the tumor microenvironment.

• Gastric Cancer Assembloids Model Tumor–Stroma Biology

  2026-10-07

  The 2025 reference study introduces patient-derived gastric cancer assembloids that combine matched tumor organoids with tumor-associated stromal cell subpopulations. Its findings show that stromal composition can reshape gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor heterogeneity, resistance, and personalized treatment selection.

• Anatabine in Alzheimer’s Research

  2026-10-06

  Anatabine is a vendor-described tobacco alkaloid research compound that reduces amyloid-beta-related readouts in neuronal-like cells and in a transgenic mouse model. The evidence supports mechanistic neurodegeneration research, but it does not establish clinical efficacy or therapeutic safety (https://www.apexbt.com/r-s-anatabine.html).

• Aconitase Assays in CD8+ T-Cell Metabolism

  2026-10-05

  A source-grounded overview of how aconitase activity measurements may complement research on CD8+ T-cell metabolism. The discussion distinguishes the direct findings of Holling et al. on the CD28–ARS2–PKM2 axis from supplier-described capabilities of the APExBIO Aconitase Activity Colorimetric Assay Kit, while defining evidence limits, interpretation boundaries, and the need for orthogonal metabolic measurements.

• Heat-Not-Burn Toxicity: Evidence and Limits

  2026-10-05

  Fu and colleagues compared the cytotoxicity and genotoxicity of a heat-not-burn product with conventional cigarette smoke across rat and cell-based models. The study’s main contribution is a comparative, multi-endpoint framework showing lower toxicity for the tested heat-not-burn product under the investigated conditions, while also demonstrating why those findings should not be interpreted as evidence of harmlessness or universal risk reduction.

• SETD7, White Adipose Browning, and T3 Research

  2026-10-04

  A 2026 study identifies SETD7 as a negative regulator of inguinal white adipose thermogenesis and links its depletion to an Adcy7–Sirt1–CREB1 pathway. The findings strengthen the case for studying adipocyte-intrinsic epigenetic control in metabolic disorder research, while remaining preclinical and distinct from direct evidence about Triiodothyronine or thyroid hormone receptor activation.

• CA-074 Me and the Lysosomal Necroptosis Frontier

  2026-10-03

  A source-grounded perspective on how cathepsin B inhibition can clarify lysosomal membrane permeabilization, necroptosis, apoptosis, and inflammatory disease models—while defining the evidence limits of chemical perturbation.

• AR Heterogeneity Shapes Castration and Enzalutamide Response

  2026-10-01

  Li and colleagues showed that heterogeneous androgen receptor expression is not merely a pathological feature of advanced prostate cancer but a determinant of castration and enzalutamide response. By combining patient samples, engineered cell models, xenografts, RNA sequencing, and combination treatment studies, the work distinguished AR-positive and AR-low or negative resistance states and identified BCL-2 as a therapeutic vulnerability.

• Ciclesonide: Translational Precision in a Degrader Era

  2026-10-01

  Ciclesonide illustrates how prodrug activation, intracellular retention, and glucocorticoid receptor pharmacology can sharpen respiratory research. This thought-leadership perspective connects that translational logic with ERAD-engaging targeted protein degradation while clearly distinguishing established evidence from forward-looking strategy.

• SNAI1, EMT, and Stemness in Thymic Tumors

  2026-10-01

  This 2024 study identifies SNAI1 as a central transcriptional regulator of epithelial–mesenchymal transition and cancer stem cell-like behavior in thymic epithelial tumors. Integrated genomic, epigenomic, single-cell, biochemical, and functional analyses connect SNAI1 to the PIK3R2/p-EphA2–GSK3β/β-catenin axis, while also implicating macrophage-state remodeling in the tumor microenvironment.

• Sulfaphenazole Restores Vasodilation in Diabetic Mice

  2026-09-30

  The reference study showed that inhibiting CYP2C with Sulfaphenazole restored acetylcholine-dependent endothelial relaxation in db/db diabetic mice without lowering plasma glucose. Its results link CYP-derived reactive oxygen species to reduced nitric oxide bioavailability, offering a mechanistic framework for vascular endothelial function research while leaving isoform specificity and clinical translation unresolved.

• AI-10-49: A Causal Assay Framework for inv(16) AML

  2026-09-29

  AI-10-49 is a selective CBFβ-SMMHC inhibitor that enables a layered investigation of fusion-protein engagement, RUNX1 reactivation, and leukemia dependence. This guide translates the inv(16) AML evidence base into practical assay decisions without treating downstream biomarkers as substitutes for target engagement.

• SETD7 Depletion Promotes Adipose Browning in Obesity

  2026-09-29

  This study identifies SETD7 as a negative regulator of inguinal white adipose tissue thermogenesis. Using mouse models, beige adipocyte cultures, and RNA-seq, the authors link SETD7 deficiency to an Adcy7–Sirt1–CREB1 pathway that enhances browning and improves resistance to high-fat diet-associated metabolic dysfunction.

• Chlorpromazine Beyond D2: A Translational Lens

  2026-09-28

  Chlorpromazine offers more than a familiar dopamine D2 receptor antagonist model. This thought-leadership analysis connects its multi-receptor pharmacology with emerging evidence on hepatic nanoparticle interactions, helping translational researchers distinguish validated biology from testable opportunity in antipsychotic research and nanomedicine.

• SNAI1 Links EMT and Stemness in Thymic Tumors

  2026-09-28

  A 2024 study identifies SNAI1 as a regulator of epithelial–mesenchymal transition and cancer stem cell-like traits in thymic epithelial tumors, connecting its transcriptional activity to PIK3R2 and phosphorylated EphA2. The combined genomic, cellular, animal, and molecular assays support a proposed signaling mechanism, while leaving therapeutic translation and clinical relevance to be tested.

7977 records 1/532 page Next 12345 下5页 Last page